AZD1152 in Patients With Advanced Solid Malignancies-Study 1
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152
when given as a continuous 2-hour infusion every week and every 2 weeks in patients with
advanced solid malignancies.